@entity136 and trastuzumab in metastatic XXXX .

@entity1 @entity0 @entity5 @entity136 @entity1722
The background, rationale, and preliminary results of a phase II trial of @entity136 plus trastuzumab in heavily pretreated metastatic @entity0 @entity1 are presented. @entity136 and trastuzumab both exhibit single-agent activity in previously treated metastatic @entity0 . Preclinical studies of @entity136 and trastuzumab in combination showed additive or synergistic antitumor effects in @entity1 @entity0 cell lines that overexpress @entity1722 . A multicenter phase II trial was thus conducted to define the safety and efficacy of @entity136 /trastuzumab in @entity1 previously treated for metastatic @entity0 . @entity1 with measurable metastatic @entity0 whose primary or secondary @entity5 overexpressed @entity1722 were eligible for inclusion. @entity136 1,200 mg/m(2) was administered on days 1 and 8 of a 21-day cycle. Trastuzumab was administered at a loading dose of 4 mg/kg initially, then at 2 mg/kg weekly thereafter. Preliminary analysis of 38 evaluable @entity1 showed that @entity136 /trastuzumab was well tolerated and had significant antitumor activity in this @entity1 population. The study is now concluded, and final analysis of the data is nearing completion. Publication of the results is anticipated in 2003.
